These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 19208898)

  • 1. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
    Moritoh Y; Takeuchi K; Hazama M
    Diabetes Obes Metab; 2010 Mar; 12(3):224-33. PubMed ID: 20151999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
    Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
    J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
    Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
    Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
    Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y
    Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
    Migoya EM; Bergeron R; Miller JL; Snyder RN; Tanen M; Hilliard D; Weiss B; Larson P; Gutierrez M; Jiang G; Liu F; Pryor KA; Yao J; Zhu L; Holst JJ; Deacon C; Herman G; Thornberry N; Amatruda J; Williams-Herman D; Wagner JA; SinhaRoy R
    Clin Pharmacol Ther; 2010 Dec; 88(6):801-8. PubMed ID: 21048706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
    Nonogaki K; Kaji T
    Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
    Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.